PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer.

Brodeur (2003)

Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol.

Hara (2012)

. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol.

Cohn (2009)

. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature.

Whitman (1985)

PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol.

Vanhaesebroeck (2012)

. Dissecting the PI3K signaling axis in pediatric solid tumors: novel targets for clinical integration. Front Oncol.

Loh (2013)

Overcoming acquired resistance to anticancer therapy: focus on the PI3KAKTmTOR pathway. Cancer Chemother Pharmacol.

Burris (2013)

. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene.

Kang (2008)

. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res.

Opel (2007)

. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene.

Johnsen (2008)

. Analysis of PI3KAKTmTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol.

Izycka-Swieszewska (2010)

. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer.

Dam (2006)

. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res.

Shukla (2012)

. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer.

Munoz (2004)

. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell.

Berry (2012)

. Oncogenic mutations of ALK kinase in neuroblastoma. Nature.

Chen (2008)

. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factorTrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res.

Li (2005)

. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res.

Liu (1998)

. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res.

Ho (2005)

. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol.

Servidei (2006)

PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell.

Hogarty (2012)

. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res.

Chesler (2006)

. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med.

Chanthery (2012)

. Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma. Cancer Cell.

Otto (2009)

Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene.

Kim (2004)

. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res.

Maloney (2003)

. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer.

Kolb (2008)

. Novel agents targeting the IGF-1RPI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One.

Wojtalla (2012)

. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer.

Guerreiro (2006)

. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res.

Tanno (2006)

. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Childrens Oncology Group phase 1 consortium study. Lancet Oncol.

Mosse (2013)

. Molecular rationale for the use of PI3KAKTmTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget.

Moore (2014)

. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett.

Burger (2011)

. A dual PI3 kinasemTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell.

Fan (2006)

. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinasemammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther.

Maira (2008)

. Sequential dosing in chemosensitization: targeting the PI3KAktmTOR pathway in neuroblastoma. PLoS One.

Westhoff (2013)

. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene.

Bender (2011)

. Effects of small molecule inhibitors of PI3KAktmTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer.

Segerstrom (2011)

. Targeting aberrant PI3KAkt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res.

Opel (2011)

. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol.

Rodon (2013)

. Comprehensive preclinical testing for neuroblastoma using orthotopic xenografts of a patient tumor. J Clin Oncol.

Federico (2012)

. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst.

Li (2010)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med.

Seto (2012)

. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer.

Houghton (2008)

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther.

Kurmasheva (2007)

. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol.

Fouladi (2007)

. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res.

Hartford (2009)

. Phase I study of temsirolimus in pediatric patients with recurrentrefractory solid tumors. J Clin Oncol.

Spunt (2011)

. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer.

Geoerger (2012)

. Targeting PI3KAKTmTOR pathway in non small cell lung cancer. Biochem Pharmacol.

Fumarola (2014)

. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis.

Zhang (2015)

. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol.

Schleiermacher (2014)

Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging

Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 659

The role of TGF-β/SMAD4 signaling in cancer

Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631

Epithelial-mesenchymal transition in tissue repair and fibrosis

Stone, R. C., Pastar, I., Ojeh, N. O., Chen, V., Liu, S., Garzon, K. I., & Tomic‐Canic, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2464-0 · Cited by 591

PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)

Xie, Y., Shi, X., Sheng, K., Han, G., Li, W., Zhao, Q., Jiang, B., Feng, J., Li, J., & Gu, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9713 · Cited by 505

Solanine Interferes with AKT/p-AKT and PI3K/p-PI3K Pathway to Inhibit HIF and Destroy Cell Energy Metabolism

Wang, Y., Wang, P., & Zhao, W. (2021) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2021.910008 · Cited by 1

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects

Dufour, M., Dormond-Meuwly, A., Pythoud, C., Demartines, N., & Dormond, O. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.014 · Cited by 21

FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

Lin, A., Piao, H.-L., Li, Z., Sarbassov, D. D., Ma, L., & Gan, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1729 · Cited by 152

Virtual Docking Screening and QSAR Studies to Explore PI3K and mTOR Inhibitors Acting on AKT in Cancers

Kandoussi, I., Benherrif, O., Lakhlili, W., et al. (2020) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079099 · Cited by 1

Solanine Interferes With AKT/p-AKT and PI3K/ p-PI3K to Inhibit HIF and Destroy Cell Energy MetabolismPreprint

Wang, P., & Wang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-663150/v1